CHRS Coherus BioSciences Inc.

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: . This webcast will be available for replay until February 10, 2023.

About Coherus

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics.

Coherus Contact Information:

Marek Ciszewski, J.D.

SVP Investor Relations

Coherus Biosciences, Inc.



EN
04/01/2023

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: . A replay of the presentation will be available on this same website for approximately 90 days. 46th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Da...

February 23, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Closing of Public Offering of Common ...

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock –The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwriting discounts and ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common ...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected t...

February 13, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Proposed Public Offering of Common St...

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shares in the Offering ar...

February 12, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcar...

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: . This webcast will be available for replay until February 13, 2026. About Coherus OncologyCoherus Onco...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch